Literature DB >> 27270422

MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.

J Lu1, G Song1, Q Tang1, J Yin1, C Zou1, Z Zhao1, X Xie1, H Xu1, G Huang1, J Wang1, D-F Lee2, R Khokha3, H Yang4, J Shen1.   

Abstract

MicroRNAs (miRNAs) are important epigenetic regulators of gene expression. Although several miRNAs have been implicated in osteosarcoma, their role in regulation of osteosarcoma cancer stem cells (CSCs) remains unknown. Here we demonstrated that miR-26a is downregulated in osteosarcoma CSCs when derived by either sarcosphere generation, chemodrug or aldehyde dehydrogenase (ALDH) activity selection. Lentiviral overexpression of miR-26a in ZOS and 143B osteosarcoma cells decreases the expression of stem cell markers and suppresses sarcosphere formation, as well as ALDH activity. Moreover, miR-26a overexpression inhibits the tumor cell growth both in vitro and in vivo. We further demonstrate that miR-26a directly target Jagged1, one of the Notch ligand, and that its tumor suppressive effects are mediated through inhibition of Jagged1/Notch signaling. Importantly, reduced miR-26a expression, as determined by in situ hybridization in patient tumors (n=92), is associated with lung metastasis and poor overall survival of osteosarcoma patients. Together, these data suggest the essential role of miR-26a/Jagged1/Notch pathway in regulating the stem cell-like traits of osteosarcoma cells and provide a potential target for osteosarcoma therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270422     DOI: 10.1038/onc.2016.194

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  Current concepts on the surgical and medical management of osteosarcoma.

Authors:  Herrick J Siegel; Joseph G Pressey
Journal:  Expert Rev Anticancer Ther       Date:  2008-08       Impact factor: 4.512

2.  The promotion of bone regeneration through positive regulation of angiogenic-osteogenic coupling using microRNA-26a.

Authors:  Yan Li; Longkun Fan; Shiyu Liu; Wenjia Liu; Hao Zhang; Tao Zhou; Dan Wu; Ping Yang; Lijuan Shen; Jihua Chen; Yan Jin
Journal:  Biomaterials       Date:  2013-04-08       Impact factor: 12.479

3.  IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling.

Authors:  Jinchang Lu; Guohui Song; Qinglian Tang; Changye Zou; Feng Han; Zhiqiang Zhao; Bicheng Yong; Junqiang Yin; Huaiyuan Xu; Xianbiao Xie; Tiebang Kang; YingLee Lam; Huiling Yang; Jingnan Shen; Jin Wang
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

Review 4.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.

Authors:  Naoko Takebe; Pamela J Harris; Ronald Q Warren; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

5.  Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases.

Authors:  Chang-ye Zou; Jin Wang; Jing-nan Shen; Gang Huang; Song Jin; Jun-qiang Yin; Qian-chen Guo; Hao-miao Li; Lan Luo; Meng Zhang; Long-Juan Zhang
Journal:  Acta Pharmacol Sin       Date:  2008-03       Impact factor: 6.150

6.  Down-regulation of miR-106b suppresses the growth of human glioma cells.

Authors:  Anling Zhang; Jianwei Hao; Kun Wang; Qiang Huang; Kai Yu; Chunsheng Kang; Guangxiu Wang; Zhifan Jia; Lei Han; Peiyu Pu
Journal:  J Neurooncol       Date:  2013-02-02       Impact factor: 4.130

7.  Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture.

Authors:  Yi Arial Zeng; Roel Nusse
Journal:  Cell Stem Cell       Date:  2010-06-04       Impact factor: 24.633

8.  Targeting the osteosarcoma cancer stem cell.

Authors:  Valerie A Siclari; Ling Qin
Journal:  J Orthop Surg Res       Date:  2010-10-27       Impact factor: 2.359

9.  Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.

Authors:  Qing-Lian Tang; Xian-Biao Xie; Jin Wang; Qiong Chen; An-Jia Han; Chang-Ye Zou; Jun-Qiang Yin; Da-Wei Liu; Yi Liang; Zhi-Qiang Zhao; Bi-Cheng Yong; Ru-Hua Zhang; Qi-Sheng Feng; Wu-Guo Deng; Xiao-Feng Zhu; Binhua P Zhou; Yi-Xin Zeng; Jing-Nan Shen; Tiebang Kang
Journal:  J Natl Cancer Inst       Date:  2012-04-24       Impact factor: 13.506

10.  MicroRNA-29b-1 impairs in vitro cell proliferation, self‑renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Francesca Pentimalli; Domenico Di Marzo; Iris Maria Forte; Antonella D'Anneo; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Antonio Giordano; Renza Vento
Journal:  Int J Oncol       Date:  2014-08-22       Impact factor: 5.650

View more
  41 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  Contextual Regulation of Skeletal Physiology by Notch Signaling.

Authors:  Daniel W Youngstrom; Kurt D Hankenson
Journal:  Curr Osteoporos Rep       Date:  2019-08       Impact factor: 5.096

Review 3.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

Review 4.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

5.  Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.

Authors:  Gen Ba; Zhongyan Hua; Ning Xu; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Cell Cycle       Date:  2020-05-13       Impact factor: 4.534

Review 6.  MicroRNAs in Bone Metastasis.

Authors:  Eric Hesse; Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

7.  Long noncoding RNA DLX6-AS1 promotes renal cell carcinoma progression via miR-26a/PTEN axis.

Authors:  Xing Zeng; Zhiquan Hu; Xinwen Ke; Huake Tang; Bolin Wu; Xian Wei; Zheng Liu
Journal:  Cell Cycle       Date:  2017-09-07       Impact factor: 4.534

8.  CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.

Authors:  Qinglian Tang; Jinchang Lu; Changye Zou; Yang Shao; Yan Chen; Swami Narala; Hui Fang; Huaiyuan Xu; Jin Wang; Jingnan Shen; Rama Khokha
Journal:  Oncogene       Date:  2018-04-03       Impact factor: 9.867

9.  miR-30 Family Reduction Maintains Self-Renewal and Promotes Tumorigenesis in NSCLC-Initiating Cells by Targeting Oncogene TM4SF1.

Authors:  Yu-Shui Ma; Fei Yu; Xiao-Ming Zhong; Gai-Xia Lu; Xian-Ling Cong; Shao-Bo Xue; Wen-Ting Xie; Li-Kun Hou; Li-Juan Pang; Wei Wu; Wei Zhang; Le-Le Cong; Tie Liu; Hui-Deng Long; Ran Sun; Hong-Yan Sun; Zhong-Wei Lv; Chun-Yan Wu; Da Fu
Journal:  Mol Ther       Date:  2018-09-13       Impact factor: 11.454

Review 10.  Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance.

Authors:  Saeedeh Keyvani-Ghamsari; Khatereh Khorsandi; Azhar Rasul; Muhammad Khatir Zaman
Journal:  Clin Epigenetics       Date:  2021-05-29       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.